Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose mirogabalin for neuropathic pain in patients undergoing hemodialysis
jRCT1071250079Recruiting
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of mirogabalin in Neuralgia, postherpetic neuralgia (PHN), diabetic polyneuropathy (DPN) and 13 more (2 arms). Primary endpoints: Change in neuropathic pain VAS score from baseline to 12 weeks (hemodialysis patients) and Steady-state mirogabalin blood concentrations (control patients). Started Sep 2025; status: recruiting.
02
Drugs
mirogabalin
03
Conditions
Neuralgiapostherpetic neuralgia (PHN)diabetic polyneuropathy (DPN)spinal stenosiscarpal tunnel syndrome (CTS)
Beyond the preview
Go deeper on jRCT1071250079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071250079.